IL-10R2 (also known as IL-10RB), which serves as the IL-22 receptor, received the most weight in the regression model as an indicator of poor prognosis and has not been studied earlier in clinical breast cancer materials at all. The gene discussed is IL10RB; the disease is breast carcinoma.